Zhengyi Yin

发表

Ryanodine receptor 1-mediated Ca2+ signaling and mitochondrial reprogramming modulate uterine serous cancer malignant phenotypes

S. Mok, Suet-Ying Kwan, K. Lu, 2021, Journal of experimental & clinical cancer research : CR.

Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand‐1 (PD‐L1) expression and increases anti‐tumour effects of T cells in multiple myeloma

N. Xu, T. Spektor, Haiming Chen, 2020, British journal of haematology.